Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

NCT00347503 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

NCT00198445 ·Status: COMPLETED ·Phase: PHASE3

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

NCT01021761 ·Status: COMPLETED ·Phase: PHASE4

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

NCT01387464 ·Status: COMPLETED ·Phase: PHASE2

Topical Bromfenac for Intraoperative Miosis and Pain Reduction

NCT03831984 ·Status: UNKNOWN ·Phase: PHASE4

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

NCT03886779 ·Status: COMPLETED ·Phase: PHASE4

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

NCT01847638 ·Status: COMPLETED ·Phase: NA

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

NCT00469690 ·Status: COMPLETED ·Phase: PHASE4

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

NCT01310127 ·Status: COMPLETED ·Phase: PHASE4

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

NCT06785090 ·Status: COMPLETED ·Phase: PHASE4

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

NCT01023724 ·Status: COMPLETED ·Phase: PHASE4

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

NCT01475877 ·Status: COMPLETED

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

NCT00824070 ·Status: COMPLETED ·Phase: PHASE1

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

NCT00758199 ·Status: COMPLETED ·Phase: PHASE4

Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients

NCT00352807 ·Status: COMPLETED ·Phase: NA

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

NCT01001806 ·Status: COMPLETED ·Phase: PHASE4

Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.

NCT01871077 ·Status: COMPLETED ·Phase: PHASE1

Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.

NCT00355446 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

NCT01193127 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

NCT00595543 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract

NCT00793091 ·Status: UNKNOWN ·Phase: PHASE2

Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care

NCT00698724 ·Status: COMPLETED ·Phase: PHASE4

Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery

NCT02137161 ·Status: COMPLETED ·Phase: PHASE4

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

NCT01535443 ·Status: COMPLETED ·Phase: PHASE1

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

NCT07178639 ·Status: RECRUITING ·Phase: NA